SCHEDULE 13G/A: BlackRock Amends Passive Stake in IRADIMED CORP, Holding 3.9% of Common Stock
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 2 to its Schedule 13G, disclosing a passive beneficial ownership of 3.9% in IRADIMED CORP's common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 496,603 shares of IRADIMED CORP's common stock.
- This represents 3.9% of the total outstanding common stock of IRADIMED CORP.
- BlackRock, Inc. holds sole voting power over 488,550 shares and sole dispositive power over 496,603 shares.
- The filing indicates that BlackRock's stake is held in the ordinary course of business and not for the purpose of changing or influencing control of IRADIMED CORP.
- The filing was made under Rule 13d-1(b), which is typically used by institutional investors holding a passive stake of less than 20%.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake, which is neutral in sentiment. It does not contain positive or negative news about the company's operations or financial performance.
Positives
- The filing indicates a continued, passive investment by a major institutional investor (BlackRock, Inc.) in IRADIMED CORP, which can be seen as a vote of confidence in the company's long-term prospects.
- The stake is below the 5% threshold for individual entities within BlackRock, reinforcing the passive nature of the investment.
Negatives
- The document does not contain information that would be considered negative regarding IRADIMED CORP's performance or outlook, as it is a beneficial ownership report from an investor.
Risks
- The document does not detail specific risks related to IRADIMED CORP's operations or financial health, as it is a disclosure of beneficial ownership by an external entity.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding IRADIMED CORP's future performance or BlackRock's investment strategy beyond the passive nature of the current holding.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure by a large institutional investor, BlackRock, Inc., indicating its passive ownership stake in IRADIMED CORP. Such filings provide transparency into significant ownership positions in publicly traded companies, allowing the market to see which major funds are invested. As a 13G, it signifies a passive investment intent, meaning BlackRock is not seeking to influence or control the issuer's management or operations.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming BlackRock's continued investment in IRADIMED CORP.
- Management: Informs management of BlackRock's passive ownership, indicating no immediate intent for activist engagement.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of the previously revoked Power of Attorney. |
| 01/21/2025 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 03/31/2025 | Date of the event which required the filing of this Schedule 13G statement. |
| 04/29/2025 | Date the Schedule 13G Amendment No. 2 was signed by BlackRock, Inc. |
Keywords
BlackRock, IRADIMED CORP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.